The Monkeypox Vaccine Monopoly
About this episode
It makes intuitive sense for companies that develop a technology to hold its intellectual property rights. But in the case of vaccines and medical treatments, IP laws slow down manufacturing and distribution and give private companies the power to make huge decisions that affect public health globally.
Guest: Zain Rizvi, researcher for advocacy group Public Citizen, specializing in pharmaceutical innovation and access to medicine.
Need to set up your Slate Plus feed? If you subscribed through Slate.com, check out our FAQ at slate.com/podcastfaqs for easy instructions. Members subscribed via Apple Podcasts get automatic access—no setup required.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time What Next: TBD | Tech, power, and the future publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from What Next: TBD | Tech, power, and the future
Meta Settled. Is it a "Reckoning?"
What Next: TBD | Tech, power, and the future
A.I. Enshittifies Everything (Still)
What Next: TBD | Tech, power, and the future
Can the Midterms Withstand Prediction Markets?
What Next: TBD | Tech, power, and the future
Are Flock Cameras Watching You?
What Next: TBD | Tech, power, and the future